Eligibility for clinical trials is unsatisfactory for patients with myelodysplastic syndromes, even at a tertiary referral center

Kathrin Nachtkamp,Josefine Stark,Andrea Kündgen,Thomas Schroeder,Corinna Strupp,Judith Strapatsas,Esther Schuler,Jennifer Kaivers,Aristoteles Giagounidis,Christina Rautenberg,Carlo Aul,Volker Runde,Rainer Haas,Guido Kobbe,Norbert Gattermann,Ulrich Germing

Leukemia Research（2021）

引用 5|浏览7

暂无评分

摘要

•Inclusion and exclusion criteria of clinical trials are too strict for MDS patients.•Rate of inclusion declines over the years 1987−2016.•Inclusion rates are lower in pharmaceutically driven trials.•MDS patients are a heterogenous group and more comorbid, less rigid criteria needed.

查看译文

关键词

Myelodysplastic syndromes,Clinical trials,Eligibility,Inclusion criteria,Exclusion criteria

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要